Patients with EGFR-mutant non-small cell lung cancer who are TKI-naïve benefited from receiving the Cyramza-Tagrisso ...

Sanofi is conducting the two-part multicenter, randomized, open-label, controlled, parallel-group study (NCT04643002) to evaluate the safety, efficacy, pharmacokinetics and biomarker data of ...

While the top- and bottom-line numbers for Lilly (LLY) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare ...

In its upcoming report, Eli Lilly (LLY) is predicted by Wall Street analysts to post quarterly earnings of $1.53 per share, reflecting an increase of 1430% compared to the same period last year.

Promising initial Phase 1 data of EO-3021 reported in August highlighting 42.8% confirmed ORR observed in Claudin 18.2-enrich ...

Another treatment your doctor may try for your EGFR-positive NSCLC is ramucirumab (Cyramza) with erlotinib (Tarceva). You get ramucirumab through an IV, and you take erlotinib by mouth.

The list including Bristol-Myers Squibb’s cancer immunotherapy Opdivo (nivolumab), Eli Lilly’s Cyramza (ramucirumab), Eisai’s Lenvima (lenvatinib), Bayer’s Stivarga (regorafenib) ...

and Eli Lilly’s anti-VEGF drug Cyramza (ramucirumab) – in advanced solid tumours. The pharma group licensed ex-China rights to tusamitamab ravtansine from Chinese biotech Innovent in 2017 ...

You might take erlotinib along with another medicine called ramucirumab, which helps slow your cancer growth by blocking new blood vessels from forming. If your advanced EGFR-positive NSCLC is a ...